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Introduction: The clinical impact of anti-HLA antibodies is one of
the major area of research in renal allograft transplantation.
Luminex Platform has emerged as the favoured technology for
detection of HLA antibodies in addition to the CDC crossmatch
(XM). Luminex DSA crossmatch has been recently introduced in
India for detecting antibodies that are missed by CDC XM. We
present our experience with the Luminex based DSA crossmatch
test done in the recipients who underwent transplantation at Sir
Ganga Ram Hospital in the year 2013-14 with one year post
transplant follow up. The objective of the study was to evaluate the
impact of the pre-Tx DSAs detected by Luminex crossmatch on the
clinical outcome of the renal graft over a period of one year
Methods: We began performing DSA (donor speciﬁc antibody)
monitoring protocol by Luminex in the year 2013 at our center. The
present study includes patients from January 2013 to December
2013 with one year follow up post kidney transplant. Pre- trans-
plant sera from 46 renal transplant recipients with a negative CDC
crossmatch were assessed for donor-speciﬁc antibodies (DSA)
detection on Luminex Platform using Lifecodes DSA kit (Immucor).
The serum samples with DSA (HLA-Class I or II or both) of MFI
(mean ﬂuorescent intensity) value more than 500 was considered to
be positive. The results were then correlated with the clinical
outcomes of the renal allograft.
Results: SAs were found in 11 out of 46 recipients (23.9%). Of the
eleven DSA positive patients, 3 patients (27.27%) developed acute
graft rejection. All these 3 patients had positive C4d staining in
their biopsies and the MFI value of the DSA on Luminex platform
was found to be more than 1000. The remaining 8 DSA positive
patients showed no rejection and had stable graft function. The MFI
value of the DSAs in these patients ranged from 500-1000. All the
35 DSA negative patients (76.1%) were also having stable graft
function in one year follow up. Hence, AMR was more frequent in
the DSA positive group than in DSA negative group. outcome of the
renal graft over a period of one year.
Conclusions: The present study evaluates the importance of
Luminex DSA crossmatch test in detecting the donor speciﬁc HLA
antibodies over the CDC crossmatch. There was a higher incidence
of AMR in patients with pre-transplant DSA despite a negative CDC
crossmatch. The present study clearly establishes that the Luminex
DSA crossmatch is helpful for predicting post transplant graft
outcome or rejection. The laboratory cut off value of the MFI for
positive DSA was increased from 500 to 1000. We suggest that DSA
MFI value above 1000 should be considered for further evaluation
by Single antigen bead assay (SAB) by Luminex. However, the
clinical impact of the pre-Tx DSAs detected by Luminex techniques
has to be fully evaluated in terms of graft survival and more
retrospective studies with larger sample size.
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common end-point of progressive kidney diseases. A multitude of
factors and processes were found to promote and aggravate renal
ﬁbrosis, but our understanding of endogenous factors limiting
ﬁbrosis is limited.
Methods: Here we analyzed the role of macrophage migration
inhibitory factor (MIF), a pleiotropic proinﬂammatory cytokine, in
animal models of renal tubulointerstitial ﬁbrosis and inﬂammation.
Results: We show that MIF expression is reduced in murine and
human renal tubulointerstitial ﬁbrosis. MIF inhibition using gene
knock-out, neutralizing antibodies or a small-molecule inhibitor
aggravated ﬁbrosis and worsened parameters of renal function,
while treatment with murine recombinant MIF abrogated renal
ﬁbrosis. This effect was consistent in three distinct models of renal
ﬁbrosis, i.e. those induced by obstruction, ischemia-reperfusion or
toxin, and was also effective when treatment was initiated in
already established ﬁbrosis. Bone-marrow chimeras showed that
local but not bone-marrow derived MIF was involved. Mechanis-
tically, MIF reduced the expression of chemokine MCP-1 in tubular
cells and reduced renal inﬂammatory inﬁltrates already early in
disease.
Conclusions: Taken together, we identiﬁed a hitherto unappreci-
ated role of MIF as an endogenous factor limiting renal tubu-
lointerstitial ﬁbrosis via limiting renal inﬂammation. Our data raise
important safety concerns regarding the envisaged use of MIF in-
hibition as a treatment for inﬂammatory diseases.
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Introduction: MPO-ANCA-associated vasculitis (MPO-AAV) is a
systemic small vessel vasuculitis that involves preferentially the
kidneys. It has been shown the pathogenic role of MPO-ANCA in
MPO-AAV. Neutrophil extracellular traps (NETs), which are
released from neutrophils activated by microorganisms, are
composed of net-like chromatin ﬁbers and antimicrobial proteins,
such as MPO. The activated neutrophils die in due course with the
formation of NETs. During the NET formation, histones bound
chromatin ﬁbers are citrullinated by peptigylarginine deiminase 4
(PAD4), and consequently the chromatin ﬁbers are decondensated.
Thus, PAD4 plays a pivotal role in the NET formation. Although
NETs are essential for elimination of microorganisms, excessive
formation of NETs has been shown to be implicated in the MPO-
ANCA production. The aim of this study is to determine that in-
hibition of PAD4 can suppress the NET formation and MPO-ANCA
production in vivo.
Methods: According to our previous report, NETs were induced in
peripheral blood neutrophils derived from healthy donors (1106/
ml) by stimulation with 20 nM phorbol myristate acetate (PMA)
with or without 20 mM anti-thyroid drug, propylthiouracil (PTU)
for 2 hours at 37 oC. The effect of PAD4 inhibitor, 200 mM Cl-
amidine, on the in vitro NET formation induced by 20 nM PMAS7
TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016with or without 20 mM PTU was determined. Next, we established
mouse models with MPO-ANCA production. BALB/c mice were
given intraperitoneal (i.p.) injection of PMA (50 ng at day 0 and
day 7) and oral administration of PTU (5 mg/day) for 2 weeks. In
this model, MPO-ANCA was produced by day 14 though an
obvious vasculitic phenotype was not observed. These mice were
divided into two groups, namely Group 1 with daily i.p. injection
of Cl-amidine (0.3 mg/200 ml/day) (n¼7) and Group 2 with daily
i.p. injection of PBS (200 ml/day) (n¼13). Two weeks later, serum
MPO-ANCA titers and amounts of peritoneal NETs were compared
between the 2 groups.
Results: In vitro NET formation induced by 20 nM PMA with or
without 20 mM PTU was inhibited signiﬁcantly by 200 mM Cl-
amidine. Serum MPO-ANCA titers of Group 1 mice (32.3  31.0 ng/
ml) were signiﬁcantly lower than those of Group 2 mice (132.1 
41.6 ng/ml). The amounts of peritoneal NETs in Group 1 mice was
signiﬁcantly smaller than those in Group 2 mice. These ﬁndings
suggested that the NET formation was inhibited signiﬁcantly by Cl-
amidine both in vitro and in vivo, and that the MPO- ANCA
production was also suppressed by Cl-amidine in vivo.
Conclusions: PAD4 inhibitor suppresses MPO-ANCA production
through inhibition of NET formation in mouse model so that it
could be a novel therapeutic modality for MPO-AAV in humans.
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Introduction: Recent research has implicated that inﬂammation may
be a key pathophysiological mechanism in diabetic nephropathy
(DN), although its pathogenesis is multifactorial. Intercellular
adhesion molecule 1 (ICAM-1) is an acute phase marker of inﬂam-
mation and the ICAM-1 gene is located on chromosome 19p13.2 and
resides a linkage region to diabetes and DN. To investigate whether
ICAM-1 has effects in the development of DN, we have recently
performed genetic and pathological studies of this molecule in
Swedish and Malaysian subjects with normal glucose tolerance
(NGT), diabetes and DN.
Methods: We genotyped six single nucleotide polymorphisms
(SNPs) in the ICAM-1 gene with TaqMan allelic discrimination. We
also determined plasma ICAM-1 levels with an enzyme-linked im-
mune-sorbent assay kit.
Results: We found that non-synonymous SNP rs5498 (K469E A/G)
was associated diabetes and DN and the G allele had a protective
effect. Particularly, we found a high heterozygous index of this
polymorphism presenting in both populations. The genotype dis-
tribution of this polymorphism was kept in Hardy-Weinberg
Equilibrium and no duplicon in the genomic sequence was found.
The ICAM-1 K469E(A/G) polymorphism resides in the 5th Ig-like
domain of ICAM-1 protein. This domain is essential for dimeriza-
tion, surface presentation and solubilisation of proteins of the
protein and subsequently plays a crucial role in the activity of
ICAM-1 protein in the interaction with LFA-1 and the adhesion of B
cells. Furthermore, we found the carriers with heterozygous ge-
notype had higher fasting glucose levels among newly diagnosed
type 2 diabetes patients compared with the subjects with wild orS8mutant homozygous genotype. Plasma ICAM-1 levels were
increased from the subjects with NGT, diabetes without DN to the
patients with DN. Among diabetic patients with DN, the carriers
with heterozygous genotype had higher plasma ICAM-1 levels
compared with other patients.
Conclusions: Our study provided evidence that ICAM-1 has effects
in the development of DN. The patients carrying with heterozygous
genotype of SNP rs5498 (K469E A/G) in the ICAM-1 gene have
higher risk susceptibility to DN. The combined approach with
genotyping this polymorphism and measuring plasma ICAM-1
levels may be useful for prediction of DN in translation medicine.
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Introduction: Acute tubular necrosis (ATN) is common in severe
acute kidney injury (AKI). Inﬁltrating neutrophils contribute to the
crescendo of renal inﬂammation and kidney injury (necroin-
ﬂammation), but how neutrophils contribute to ATN is not clear.
We hypothesized that inﬁltrating neutrophils release neutrophil
extracellular traps (NETs), which implies the release of cytotoxic
DAMPs like histones that accelerate ATN and AKI.
Methods: In vivo; Postischemic AKI was induced in wild type mice
by unilateral clamping of the renal pedicle for 35 minutes followed
by reperfusion for 6h or 72h. Formation of NETs was identiﬁed by
immunostaining using citrullinated histone 3 (CitH3) antibody.
Intravascular NETs were conﬁrmed by neutrophil elastase (NE)-
DNA complex ELISA in plasma. Renalcell death was evaluated in
kidney sections by Tunel staining and PicoGreen DNA assay of
plasma. To investigate the effect of NETs inhibition in bilateral IRI
(ischemic 35min, reperfusion 24h) group of mice were treated with
either PAD inhibitor (PADin) or neutrophil depletion and sacriﬁced
24h after reperfusion. In vitro; To investigate whether hypoxia can
directly induce NETs formation or indirectly via hypoxia-induced
tubular cell death, 1) human neutrophils were incubated in 1% or
20%O2 for 24h, 2) the media of tubular cell line (TC), which were
incubated in 1% or 20%O2 for 24h, and stimulated with neutro-
phils for 4h. Furthermore, PMA or histone- induced NETs were
treated by PADin, anti-histone antibody and heparin. Histone-
stimulated neutrophil media were applied to TC. NETs and TC
injury in vitro were evaluated by CitH3 staining/MPO-DNA com-
plex and LDH assay, respectively.
Results: IRI kidney showed increased positivity for CitH3 in areas
of tubular necrosis of the outer medulla. Plasma levels of the NE-
DNA complex were increased in a time-dependent manner as
compared to sham-operated mice. NET-induced renal cell death was
shown in terms of increased Tunel positive area in kidney and
plasma DNA 6h after reperfusion compared to the sham group.
Subsequently, NETs in plasma and kidney increased 15w24h after
reperfusion. In bilateral IRI, treatment with both PADin and
neutrophil depletion signiﬁcantly reduced the plasma levels of NE-
DNA complex and NETs area in kidney compared to the vehicle
group. Treatment further improved renal excretory function in
terms of reducing plasma creatinine levels. In vitro, the NET-Kidney International Reports (2016) 1, S1–S22
